The biotech: Relypsa
Round: $62.4 million
Based: Santa Clara, CA
President: Gerrit Klaerner
Investors: 5AM Ventures, Delphi Ventures, Mediphase Venture Partners, New Leaf Venture Partners, OrbiMed Advisors, Sibling Capital, Sprout Group.

The scoop: Relypsa needs the cash to put patiromer--or RLY5016--through a pivotal study for hyperkalemia, a condition in which high levels of potassium threaten patients suffering from diabetes, heart failure, and kidney disease with a potentially lethal case of arrhythmia. You may recall that this became Relypsa's lead asset after Amgen ($AMGN) bought out Ilypsa, plucked out the drug it really wanted, and let the company move on to Chapter II with a pipeline it was intimately familiar with. The Phase III gets under way before the end of the year. FierceBiotech named Relypsa a Fierce 15 company way back in 2008, when some very devoted venture backers came up with $70 million for development work. Sibling Capital joined the group on this recent investment. For the record, Relypsa announced the round at $80 million, though the NVCA stats include money banked in the quarter.

For more:
Special Report: Relypsa - 2008 Fierce 15
Relypsa completes $80M round as it preps pivotal heart study
Relypsa reloads with $50M to support late-stage drug quest
Relypsa banks $70M Series B for pivotal trial work


Suggested Articles

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.

Fresh off Tilos Therapeutics’ $773 million sale to Merck, Barbara Fox is taking the helm of another Cambridge-based company: Rheos Medicines.

The data tee Seattle Genetics up to file for FDA approval of a TKI inhibitor it paid $614 million to acquire last year.